The Vision Council releases report on managed vision care insights

News
Article

The survey for the report was conducted from December 13, 2024 to January 10, 2025 with a nationally representative samples of 1500 US adults and 150 eye care providers from The Vision Council’s Research Advisory Panel.

Hand with magnifying glass and medical insurance graphics Image credit: AdobeStock/Kiattisak

Image credit: AdobeStock/Kiattisak

New research released by The Vision Council has found that patients’ overall satisfaction in managed vision care (MVC) plans increased between 2023 and 2024, among other findings.1 The Focused inSights 2025: Managed Vision Care report provides details on how individuals enroll in MVC plans, their satisfaction with current vision insurance providers, levels of coverage for products and services, and how MVC coverage informs consumer choices concerning eye care providers and optical purchases, according to the news release.

“The findings in this report show an increasing satisfaction with managed vision care plans, especially with those with individual plans, which saw the largest year-over-year improvement,” said Alysse Henkel, vice president of Research and inSights at The Vision Council, in the release. “As consumers navigate their options, it is essential that they understand their benefits clearly to maximize their coverage and maintain satisfaction with their providers.”

The survey for the report was conducted from December 13, 2024 to January 10, 2025 with a nationally representative samples of 1500 US adults and 150 eye care providers from The Vision Council’s Research Advisory Panel.1

According to the report, individual plans showed the largest growth in satisfaction with 13 percentage points. The Net Promoter Score also improved significantly for individual, Medicaid, and Medicare plans in 2024 when compared to 2023. Those with individual and Medicaid plan members showed an increased interest in keeping their vision insurance coverage. Medicare plan members also were found to be the most likely to switch their current vision insurance provider in 2024. While confidence in individuals understanding their plan benefits remained high in 2024, Medicaid members reported the lowest confidence levels in both 2023 and 2024.1

Additionally, 8 out of 10 eye care providers reported accepting EyeMed and VSP, making them the most commonly accepted plans for both Medicare and private payor plans. Most eye care providers reported accepting some form of managed vision care.1

The full report can be found on The Vision Council’s Research Download Center.

Reference:
  1. New research from The Vision Council reveals trends in managed vision care. News release. March 4, 2025. Accessed March 13, 2025. https://thevisioncouncil.org/blog/new-research-vision-council-reveals-trends-managed-vision-care

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
© 2025 MJH Life Sciences

All rights reserved.